Activation of these signal pathways leads to the development of chemoresistance and tumour progression, thus highlighting the relevance of targeting CXCR4-mediated signalling in resistant TNBC with poor therapeutic response [11]. The gene discussed is CXCR4; the disease is neoplasm.